Orthopedic University Hospital Balgrist, University of Zurich, Faculty of Medicine, Forchstrasse 340, 8008, Zurich, Switzerland,
Eur Radiol. 2015 Jan;25(1):267-73. doi: 10.1007/s00330-014-3403-7. Epub 2014 Aug 29.
To assess patients' outcomes after subacromial or glenohumeral injections based on the degree of lateral extension of the acromion.
307 patients were prospectively included after therapeutic fluoroscopy-guided subacromial (n = 148) or glenohumeral (n = 159) injections with anaesthetic and long-acting corticosteroids. Pre- and post-injection outcomes at 1 week and 1 month were obtained using the 11-point numerical rating scale (NRS) for pain. Lateral extension of the acromion was quantified and categorized by the critical shoulder angle (CSA) and the acromion index (AI) on anteroposterior conventional radiographs.
Patients' outcomes at 1 week and 1 month were significantly improved (p < 0.001) compared to baseline for subacromial and glenohumeral injection patients. Patients with a CSA <35° showed significantly higher pain reduction 1 month after subacromial injection compared to patients with a CSA >35° (4.2 ± 2.6 vs. 3.2 ± 3.0, p = 0.04). A significant difference in the 1-month NRS change in pain scores is noted for smaller AIs after subacromial injection (4.3 ± 2.8 vs. 2.6 ± 2.9; p = 0.01). No significant association was noted between clinical outcome and the lateral extension of the acromion after glenohumeral joint injections.
A short lateral extension of the acromion was associated with better clinical outcomes in subacromial injection patients but not in glenohumeral injection patients.
• Patients' outcomes at 1 month improved significantly compared to baseline for subacromial injections. • Patients' outcomes at 1 month improved significantly compared to baseline for glenohumeral injections. • Short acromial lateralization was associated with better clinical outcome after subacromial injection. • The acromial lateralization was not associated with clinical outcome after glenohumeral injection.
根据肩峰外侧延伸程度评估肩峰下或盂肱关节注射后的患者结局。
对 307 例经治疗性荧光透视引导下肩峰下(n = 148)或盂肱关节(n = 159)注射麻醉和长效皮质类固醇的患者进行前瞻性研究。使用 11 分数字评分量表(NRS)在注射前和注射后 1 周和 1 个月评估疼痛的改善情况。在前后位常规 X 线片上,通过临界肩峰角(CSA)和肩峰指数(AI)对肩峰的外侧延伸进行量化和分类。
与基线相比,肩峰下和盂肱关节注射患者在 1 周和 1 个月时的结局均明显改善(p < 0.001)。CSA < 35°的患者在肩峰下注射后 1 个月的疼痛缓解明显高于 CSA > 35°的患者(4.2 ± 2.6 比 3.2 ± 3.0,p = 0.04)。肩峰下注射后,较小的 AI 与 1 个月时 NRS 疼痛评分的变化显著相关(4.3 ± 2.8 比 2.6 ± 2.9;p = 0.01)。盂肱关节注射后,肩峰外侧延伸与临床结局之间无显著相关性。
肩峰短外侧延伸与肩峰下注射患者的临床结局较好相关,但与盂肱关节注射患者的临床结局无关。
肩峰下注射患者在 1 个月时的结局较基线明显改善。
盂肱关节注射患者在 1 个月时的结局较基线明显改善。
肩峰下注射后,肩峰短外侧化与临床结局较好相关。
肩峰外侧化与盂肱关节注射后临床结局无关。